Project Grant R03AG098647
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded the University of South Carolina $249,000 on August 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the effects of frontotemporal dementia and amyotrophic lateral sclerosis mutations in RNA-binding proteins on mRNA transport and local translation. The research uses induced pluripotent stem cell-derived neurons with CRISPR-edited FTD/ALS mutations in RNA-binding proteins (TDP-43, FUS, HNRNPA1, HNRNPA2, MATR3, and TIA1) to determine...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded the University of Pittsburgh $664,619 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop multiscale computational and experimental models of neurometabolic coupling across age-related cognitive decline and late-onset Alzheimer's disease. The research integrates in vivo two-photon microscopy, multispectral wide-field imaging, and magnetic resonance imaging to characterize the relationship between neuronal activity and metabolic...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of semaphorin 3A in microglial activation and Alzheimer's disease pathology. The research will determine the functional role and mechanistic basis for semaphorin 3A–mediated regulation of microglial activation in Alzheimer's disease. Building on preliminary findings using human induced pluripotent...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded the University of Southern California $695,789 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop HGEA-NET, a multiscale computational model of the hippocampus that integrates cell type-specific gene expression and connectivity data to understand how progressive neurodegeneration of vulnerable neuronal populations leads to hippocampal network dysfunction and cognitive decline in Alzheimer's disease. The project builds on USC's...
- The National Institute on Aging awarded The Medical University of South Carolina $443,940 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the link between Alzheimer's disease and improved anti-cancer immunity through regulation of mitochondrial ceramide metabolism in T-cells. The research tests the hypothesis that amyloid precursor protein and amyloid-beta peptides accumulate in T-cell mitochondria of aging patients with Alzheimer's disease, inhibiting...
- The National Institute on Aging awarded The Salk Institute for Biological Studies $1.359 million on February 15, 2026, under the Aging Research program (CFDA 93.866) to characterize activity-dependent changes to neuronal populations in the spinal dorsal horn during aging and determine functional consequences for sensorimotor behaviors. The research selectively perturbs activity in different classes of cutaneous afferent neurons to identify inputs that support cell survival in adult mice,...
- The National Institute on Aging awarded Drexel University $420,554 under Aging Research (CFDA 93.866) on September 1, 2026, to establish an integrated system for studying senescence and aging in the central nervous system. The award funds two research aims: characterization of the molecular and functional consequences of senescence in astrocyte and neuronal cultures, and evaluation of senescence impact in a multicellular context using hiPSC-derived vascularized cortical organoids. Single-cell...
The National Institute on Aging awarded the University of South Carolina $322,500 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the molecular and cellular mechanisms of cognitive decline in aging and Alzheimer's disease, with focus on D-serine metabolism and NMDAR signaling in the hippocampus. The research uses rodent models and human tissue samples to examine the roles of serine racemase and D-amino acid oxidase in hippocampal learning, memory, and NMDAR function across aging and disease stages. The project hypothesis posits that aging impairs cognition through reduced neuronal serine racemase expression, while Alzheimer's disease pathology stems from increased glial serine racemase and compensatory upregulation of D-amino acid oxidase. Aim 1 employs viral vectors to modulate serine racemase expression in neurons and glial cells of the hippocampus in TgF344-AD rats, followed by behavioral testing, molecular assays, and electrophysiological recordings to examine NMDAR activity and pathology. Performance occurs in Columbia, South Carolina. The award period runs from September 1, 2026, through August 31, 2028. This is a Project Grant, classified as an exploratory or developmental award that is not eligible for renewal under program rules.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $322.5k | 8/28/26 |